Direct and Indirect Effects of Fibroblast Growth Factor 23 on the Heart

Overview

Journal Front Endocrinol (Lausanne)

Specialty Endocrinology

Date 2023 Mar 13

PMID 36909314

Authors

Toshiaki Nakano

Hiroshi Kishimoto

Masanori Tokumoto

Affiliations

Soon will be listed here.

Abstract

Fibroblast growth factor (FGF)23 is a bone-derived phosphotropic hormone that regulates phosphate and mineral homeostasis. Recent studies have provided evidence that a high plasma concentration of FGF23 is associated with cardiac disease, including left ventricular hypertrophy (LVH), heart failure, atrial fibrillation, and cardiac death. Experimental studies have shown that FGF23 activates fibroblast growth factor receptor 4 (FGFR4)/phospholipase Cγ/calcineurin/nuclear factor of activated T-cells signaling in cardiomyocytes and induces cardiac hypertrophy in rodents. Activation of FGFR4 by FGF23 normally requires the co-receptor α-klotho, and klotho-independent signaling occurs only under conditions characterized by extremely high FGF23 concentrations. Recent studies have demonstrated that FGF23 activates the renin-angiotensin-aldosterone system (RAAS) and induces LVH, at least in part as a result of lower vitamin D activation. Moreover, crosstalk between FGF23 and RAAS results in the induction of cardiac hypertrophy and fibrosis. In this review, we summarize the results of studies regarding the relationships between FGF23 and cardiac events, and describe the potential direct and indirect mechanisms whereby FGF23 induces LVH.

Citing Articles

Anti-Inflammatory Role of the Klotho Protein and Relevance to Aging.

Prudhomme G, Wang Q Cells. 2024; 13(17.

PMID: 39272986 PMC: 11394293. DOI: 10.3390/cells13171413.

Management of Chronic Heart Failure in Dialysis Patients: A Challenging but Rewarding Path.

Guo L, Ji Y, Sun T, Liu Y, Jiang C, Wang G Rev Cardiovasc Med. 2024; 25(6):232.

PMID: 39076321 PMC: 11270084. DOI: 10.31083/j.rcm2506232.

Erythropoietin alleviates lung ischemia-reperfusion injury by activating the FGF23/FGFR4/ERK signaling pathway.

Jin X, Jin W, Li G, Zheng J, Xu X PeerJ. 2024; 12:e17123.

PMID: 38560469 PMC: 10981413. DOI: 10.7717/peerj.17123.

Cardiac and Renal Fibrosis, the Silent Killer in the Cardiovascular Continuum: An Up-to-Date.

Chiuariu T, Salaru D, Ureche C, Vasiliu L, Lupu A, Lupu V J Cardiovasc Dev Dis. 2024; 11(2).

PMID: 38392276 PMC: 10889423. DOI: 10.3390/jcdd11020062.

Fibroblast growth factor 23 and calcium-phosphate metabolism in relation to cardiovascular risk factors in patients with type 1 diabetes.

Vermeulen S, Scheffer-Rath M, Besouw M, Van der Vaart A, de Borst M, Boot A J Diabetes. 2023; 16(6):e13500.

PMID: 38124483 PMC: 11128753. DOI: 10.1111/1753-0407.13500.

References

Ornitz D, Itoh N . Fibroblast growth factors. Genome Biol. 2001; 2(3):REVIEWS3005. PMC: 138918. DOI: 10.1186/gb-2001-2-3-reviews3005. View

Hao H, Li X, Li Q, Lin H, Chen Z, Xie J . FGF23 promotes myocardial fibrosis in mice through activation of β-catenin. Oncotarget. 2016; 7(40):64649-64664. PMC: 5323105. DOI: 10.18632/oncotarget.11623. View

Leifheit-Nestler M, Haffner D . Paracrine Effects of FGF23 on the Heart. Front Endocrinol (Lausanne). 2018; 9:278. PMC: 5985311. DOI: 10.3389/fendo.2018.00278. View

Schon A, Leifheit-Nestler M, Deppe J, Fischer D, Bayazit A, Obrycki L . Active vitamin D is cardioprotective in experimental uraemia but not in children with CKD Stages 3-5. Nephrol Dial Transplant. 2020; 36(3):442-451. DOI: 10.1093/ndt/gfaa227. View

Yilmaz M, Sonmez A, Saglam M, Yaman H, Kilic S, Demirkaya E . FGF-23 and vascular dysfunction in patients with stage 3 and 4 chronic kidney disease. Kidney Int. 2010; 78(7):679-85. DOI: 10.1038/ki.2010.194. View

Dorr K, Kammer M, Reindl-Schwaighofer R, Lorenz M, Marculescu R, Poglitsch M . The Effect of FGF23 on Cardiac Hypertrophy Is Not Mediated by Systemic Renin-Angiotensin- Aldosterone System in Hemodialysis. Front Med (Lausanne). 2022; 9:878730. PMC: 9086596. DOI: 10.3389/fmed.2022.878730. View

Parker B, Schurgers L, Brandenburg V, Christenson R, Vermeer C, Ketteler M . The associations of fibroblast growth factor 23 and uncarboxylated matrix Gla protein with mortality in coronary artery disease: the Heart and Soul Study. Ann Intern Med. 2010; 152(10):640-8. PMC: 3079370. DOI: 10.7326/0003-4819-152-10-201005180-00004. View

Touchberry C, Green T, Tchikrizov V, Mannix J, Mao T, Carney B . FGF23 is a novel regulator of intracellular calcium and cardiac contractility in addition to cardiac hypertrophy. Am J Physiol Endocrinol Metab. 2013; 304(8):E863-73. PMC: 3625783. DOI: 10.1152/ajpendo.00596.2012. View

Grabner A, Schramm K, Silswal N, Hendrix M, Yanucil C, Czaya B . FGF23/FGFR4-mediated left ventricular hypertrophy is reversible. Sci Rep. 2017; 7(1):1993. PMC: 5434018. DOI: 10.1038/s41598-017-02068-6. View

10.

Bockmann I, Lischka J, Richter B, Deppe J, Rahn A, Fischer D . FGF23-Mediated Activation of Local RAAS Promotes Cardiac Hypertrophy and Fibrosis. Int J Mol Sci. 2019; 20(18). PMC: 6770314. DOI: 10.3390/ijms20184634. View

11.

Lutsey P, Alonso A, Selvin E, Pankow J, Michos E, Agarwal S . Fibroblast growth factor-23 and incident coronary heart disease, heart failure, and cardiovascular mortality: the Atherosclerosis Risk in Communities study. J Am Heart Assoc. 2014; 3(3):e000936. PMC: 4309096. DOI: 10.1161/JAHA.114.000936. View

12.

Li Y, Kong J, Wei M, Chen Z, Liu S, Cao L . 1,25-Dihydroxyvitamin D(3) is a negative endocrine regulator of the renin-angiotensin system. J Clin Invest. 2002; 110(2):229-38. PMC: 151055. DOI: 10.1172/JCI15219. View

13.

Mizobuchi M, Nakamura H, Tokumoto M, Finch J, Morrissey J, Liapis H . Myocardial effects of VDR activators in renal failure. J Steroid Biochem Mol Biol. 2010; 121(1-2):188-92. PMC: 2906634. DOI: 10.1016/j.jsbmb.2010.03.026. View

14.

Okamoto K, Fujii H, Watanabe K, Goto S, Kono K, Nishi S . Changes of FGF23 and the Renin-Angiotensin-System in Male Mouse Models of Chronic Kidney Disease and Cardiac Hypertrophy. J Endocr Soc. 2022; 6(2):bvab187. PMC: 8758403. DOI: 10.1210/jendso/bvab187. View

15.

Roger V, Go A, Lloyd-Jones D, Benjamin E, Berry J, Borden W . Heart disease and stroke statistics--2012 update: a report from the American Heart Association. Circulation. 2011; 125(1):e2-e220. PMC: 4440543. DOI: 10.1161/CIR.0b013e31823ac046. View

16.

Ter Maaten J, Voors A, Damman K, van der Meer P, Anker S, Cleland J . Fibroblast growth factor 23 is related to profiles indicating volume overload, poor therapy optimization and prognosis in patients with new-onset and worsening heart failure. Int J Cardiol. 2018; 253:84-90. DOI: 10.1016/j.ijcard.2017.10.010. View

17.

Andersen I, Huntley B, Sandberg S, Heublein D, Burnett Jr J . Elevation of circulating but not myocardial FGF23 in human acute decompensated heart failure. Nephrol Dial Transplant. 2015; 31(5):767-72. DOI: 10.1093/ndt/gfv398. View

18.

Souma N, Isakova T, Lipiszko D, Sacco R, Elkind M, DeRosa J . Fibroblast Growth Factor 23 and Cause-Specific Mortality in the General Population: The Northern Manhattan Study. J Clin Endocrinol Metab. 2016; 101(10):3779-3786. PMC: 5052338. DOI: 10.1210/jc.2016-2215. View

19.

Ben-Dov I, Galitzer H, Lavi-Moshayoff V, Goetz R, Kuro-O M, Mohammadi M . The parathyroid is a target organ for FGF23 in rats. J Clin Invest. 2007; 117(12):4003-8. PMC: 2066196. DOI: 10.1172/JCI32409. View

20.

Leifheit-Nestler M, Siemer R, Flasbart K, Richter B, Kirchhoff F, Ziegler W . Induction of cardiac FGF23/FGFR4 expression is associated with left ventricular hypertrophy in patients with chronic kidney disease. Nephrol Dial Transplant. 2015; 31(7):1088-99. PMC: 6388939. DOI: 10.1093/ndt/gfv421. View